Since no PDX model for bladder cancer has been developed in Iran up to now, the purpose of this study was to establish and characterize the first autochthonous PDXs for MIBC via implanting the patient tumors into immunodeficient mice. Notably, we used some novel treatment targets (i.e., PD-L1, EGFR, Nectin4, and HER2) and immunophenotype indicators (Ki67, P63, GATA3, KRT5/6, KRT20, E-cadherin, and 34βE12), as immunohistochemical markers to determine the fidelity in characteristics of the established models. This evidence concerns the gene ERBB2 and urinary bladder cancer.